Decision Resources forecasts multiple myeloma drug market to more than double from $2.1B in 2008 to $5.3B in 2018

Published on March 22, 2010 at 9:48 AM · No Comments

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the multiple myeloma drug market will more than double from $2.1 billion in 2008 to $5.3 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Continued on Next page >>

Findings on cell working could lead to test and therapy for kidney failure caused by E. coliNew findings by St. Michael's researchers about the way cells work could lead to a test and therapy ...
First Edition: November 14, 2011In today's headlines, reports about the Supreme Court's expected health law announcement; about wher...
Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics...
Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPHÆterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, ...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.